Legend Biotech Corp Annual Report - A Closer Look

Let's explore Legend Biotech's performance this past year. We'll break down their latest 20-F filing into easy-to-understand insights, highlighting the key details that matter for your investment decisions. This summary aims to provide a clearer picture of where the company stands and where it's headed.

1. Business Overview

Legend Biotech is an innovative biotechnology company that develops cell therapies, primarily for cancer. Its flagship product, CARVYKTI (also known as cilta-cel), is a groundbreaking CAR T-cell therapy designed to treat multiple myeloma, a type of blood cancer.

Over the past year (reflecting 2023 performance and 2024 outlook), Legend Biotech significantly advanced CARVYKTI's market presence. In 2024, the company achieved a major milestone: the expansion of CARVYKTI's approval to treat second-line multiple myeloma (2LMM). This means the therapy can now be used much earlier in a patient's treatment journey, dramatically increasing the eligible patient population and market opportunity. Looking ahead, Legend Biotech anticipates CARVYKTI approval in Japan by the Ministry of Health, Labour and Welfare in 2025, which would unlock another major global market.

The company's business model relies heavily on strategic collaborations with larger pharmaceutical companies, such as Janssen (for CARVYKTI) and, more recently, Novartis. These partnerships generate revenue from upfront payments, milestone payments tied to development and regulatory achievements, and reimbursements for development costs. This approach shares both the financial burden and potential rewards of drug development.

2. Financial Performance

Legend Biotech primarily generates revenue from its collaboration agreements. For the Janssen partnership, this includes an initial upfront payment, significant milestone payments triggered by manufacturing progress, clinical development achievements, regulatory approvals (like the recent 2LMM expansion), and future sales targets. The Novartis collaboration, initiated in late 2023, also contributes through an upfront payment, licensing fees for intellectual property, and reimbursement for development costs, particularly for completing a Phase 1 trial.

As a biotechnology company in the development and early commercialization phase, Legend Biotech has historically reported net losses. This is because substantial investments are required for research, development, clinical trials, and manufacturing scale-up. Investors often focus on the rate of revenue growth from CARVYKTI sales (through the Janssen partnership) and the company's trajectory towards profitability as CARVYKTI gains wider adoption and enters new markets. Key metrics include CARVYKTI's gross margin and the efficiency of R&D spending. Beyond revenue, Legend Biotech measures growth by expanding CARVYKTI's approved indications (such as 2LMM), entering new geographical markets (like Japan), and advancing its pipeline through new collaborations or internal development programs.

3. Management Discussion and Analysis (MD&A) Highlights

The MD&A typically discusses the company's operational results, liquidity, and capital resources.

Results of Operations: Strategic achievements and challenges significantly drive Legend Biotech's operational performance. Key achievements this year include:

• Significant Market Expansion for CARVYKTI: In 2024, the approval of CARVYKTI for second-line multiple myeloma (2LMM) marked a transformative event. This makes the therapy available to a much larger patient population earlier in their disease progression and is expected to drive substantial revenue growth from collaboration agreements.
• Anticipated New Market Entry: Expected approval of CARVYKTI in Japan in 2025 promises to open a substantial new geographical market, further boosting global sales potential.
• Strategic New Collaboration: A new partnership with Novartis, forged in late 2023, involves licensing intellectual property and development work. This signals continued innovation, potential diversification of the company's pipeline and revenue streams, and contributes to collaboration revenue.
• Successful Capital Raising: In 2023, the company successfully raised capital through a private placement with institutional investors and a follow-on public offering. This strengthened its balance sheet and funded ongoing research and development efforts.

Challenges and Focus Areas:

• Manufacturing and Supply Chain: Scaling up CARVYKTI manufacturing to meet increasing demand, especially with new approvals, remains a critical operational challenge. Ensuring consistent supply and quality is paramount, impacting cost of goods sold and operational efficiency.
• Commercialization Execution: Successfully penetrating new markets and expanding adoption in existing ones requires robust commercial strategies and execution from its partner, Janssen.
• Intense Competition: The multiple myeloma treatment landscape is highly competitive, featuring established and emerging therapies. Maintaining CARVYKTI's competitive edge and market share presents an ongoing challenge.
• Regulatory Hurdles: While successful with 2LMM, all biotech companies face ongoing regulatory scrutiny for existing and pipeline products. This can impact timelines and market access.

Liquidity and Capital Resources: The MD&A details the company's cash flows from operating, investing, and financing activities. Successful capital raises in 2023 significantly bolstered the company's cash position, providing a runway for continued operations and development. Legend Biotech continues to invest heavily in research and development, alongside general and administrative expenses, to support its growing operations and commercialization efforts.

Critical Accounting Policies: The MD&A also outlines critical accounting policies, such as revenue recognition for collaboration agreements, research and development expenses, and valuation of intangible assets. These policies are crucial for understanding the reported financial results.

4. Financial Health

Legend Biotech's financial health is crucial for sustaining its long development cycles. The 20-F filing provides specific figures on:

• Cash and Equivalents: The total amount of readily available cash to fund operations, research and development (R&D), and potential capital expenditures.
• Burn Rate: How quickly the company spends its cash reserves, which is critical for forecasting how long current cash can last.
• Debt Levels: The amount of outstanding debt and its repayment schedule, which can impact financial flexibility.
• Capital Raising: Successful capital raises in 2023 significantly bolstered the company's cash position, providing a runway for continued operations and development and thereby improving liquidity.

The mention of "Losses Available For Offsetting Against Future Taxable Profits" indicates that, like many development-stage biotech firms, Legend Biotech has accumulated past losses. These losses can reduce future tax liabilities once the company becomes profitable, offering a potential future tax benefit. Understanding the specific amounts of Issued Capital, Share Premium, Retained Earnings, and Lease Liabilities provides a detailed view of the company's equity structure and long-term obligations and commitments.

5. Future Outlook

The continued expansion of CARVYKTI significantly shapes Legend Biotech's future outlook. The 2024 approval for 2LMM and the anticipated 2025 approval in Japan are expected to be major drivers of revenue growth and market penetration. The new collaboration with Novartis also points to ongoing research and development efforts. These could lead to new products or expanded indications, diversifying future revenue streams. Legend Biotech's strategy remains focused on leveraging CARVYKTI's success, exploring new therapeutic areas, and maintaining strong partnerships to drive long-term growth. Company leadership aims for disciplined R&D, strategic collaborations, and efficient commercialization through partners.

6. Competitive Position

Legend Biotech positions itself as a leader in innovative cell therapies, particularly with CARVYKTI's strong efficacy profile in multiple myeloma. CARVYKTI's 2LMM approval further strengthens its competitive standing by allowing earlier intervention. In the competitive multiple myeloma landscape, CARVYKTI competes with other CAR T-cell therapies (e.g., Abecma), bispecific antibodies (e.g., Tecvayli, Elrexfio), and other established drug classes. Legend Biotech's strategy emphasizes CARVYKTI's differentiated clinical profile and the potential for pipeline expansion through its proprietary cell therapy platforms. The broader trend towards personalized medicine and advanced cell therapies, particularly in oncology, provides a favorable environment for Legend Biotech to maintain and grow its competitive edge.

7. Risk Factors

Investing in biotech carries inherent risks, and Legend Biotech is no exception. Key risks disclosed in the 20-F include:

• Clinical Trial Outcomes: Future clinical trials for CARVYKTI in new indications or for other pipeline candidates may not achieve desired efficacy or safety profiles, potentially leading to delays or failures.
• Regulatory Approvals: While successful with 2LMM, future regulatory approvals are never guaranteed. They can be subject to delays, rejections, or additional requirements, impacting market access and timelines.
• Commercialization and Market Adoption: Effectively commercializing CARVYKTI and achieving broad market adoption, particularly in new regions like Japan, is critical. This depends on factors such as pricing, reimbursement, and physician acceptance.
• Competition: New or improved treatments from competitors could impact CARVYKTI's market share, pricing power, and overall commercial success.
• Manufacturing and Supply Chain: Any disruptions, quality control issues, or capacity limitations in CARVYKTI's complex manufacturing process could impact product availability, sales, and patient access.
• Intellectual Property Protection: Maintaining, defending, and enforcing intellectual property rights for CARVYKTI and other assets is vital against potential infringement or challenges.
• Reliance on Collaborators: A significant portion of Legend Biotech's success depends on the performance, strategic decisions, and financial stability of partners like Janssen and Novartis.
• Need for Additional Capital: While Legend Biotech recently raised capital, continued R&D, clinical development, and commercial expansion may require further financing. This could dilute existing shareholders or be unavailable on favorable terms.
• Market Trends and Regulatory Changes: Changes in healthcare reimbursement policies, drug pricing regulations, or broader economic conditions could adversely affect Legend Biotech's business and financial results.